Imagion Receive Positive FDA Feedback for HER2 Phase 2 Trial
Released
Released
Announcement PDF
Company Announcement
IMAGION BIOSYSTEMS LIMITED
ASX: IBX
10 July 2025
Imagion Receives Positive Feedback from FDA for HER2 Breast Cancer
Phase 2 Clinical Trial
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving
healthcare outcomes through the early detection of cancer utilising its proprietary MagSense®
HER2 imaging technology, is pleased to provide shareholders with an update regarding the
Company’s planned Phase 2 HER2 Breast Cancer clinical trial to be conducted in the U.S.
As previously advised in Company ASX releases, the IBX clinical team has been in communication
with the U.S. Food and Drug Administration (FDA) regarding plans to submit an Investigational
New Drug (IND) application for its MagSense® HER2 imaging agent. The Company can now confirm
it has recently received formal written feedback from the FDA which included positive feedback
and constructive input regarding the study plan and outcomes. This is part of the formal review
process for FDA approved clinical trials, and the Company will be meeting with the FDA in person
in the coming week to complete this process, ahead of the formal IND submission.
“I’m very pleased with the trajectory of our communications with the FDA”, said Bob Proulx,
Executive Chairman. “We view the feedback from the FDA as very encouraging and can now
confidently press forward with the formal submission and plans for undertaking the Phase 2
clinical study knowing we are in good shape regarding the regulatory path.”
The company expects to file the Investigational New Drug (IND) application for the Phase 2 study
in the third quarter of the 2025 calendar year.
Authorisation & Additional Information
This announcement was authorised by the Board of Imagion Biosystems Limited.
About Imagion Biosystems
ENDS
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular
imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect
cancer and other diseases earlier and with higher specificity than is currently possible.
For more information, visit https://imagionbiosystems.com/investor-hub/
Imagion Biosystems Limited
ASX: IBX ACN 616 305 027
Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000
http://www.imagionbiosystems.com/ | investor@imagionbio.com
Company Announcement
Media & Investor Relations:
Email: info@imagionbio.com
AU: +61 3 9692 7222
Imagion Biosystems Limited
ASX: IBX ACN 616 305 027
Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000
http://www.imagionbiosystems.com/ | investor@imagionbio.com
Share your feedback
Discover